Drugs / GFB-024
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04880291 Comparator | May 2021 → Feb 2022 | diabetes mellitus, diabetic kidney disease | Goldfinch Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFB-024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04880291 ↗ |
| Action | Inhibit | “Peripherally acting Cannabinoid-1 receptor inverse agonist” NCT04880291 ↗ |
| Modality | Monoclonal antibody | “Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody” NCT04880291 ↗ |